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Abstract
Background: Parkinson's disease (PD) is a movement disorder caused by the degeneration of
dopaminergic neurons in the substantia nigra of the midbrain. The molecular basis of this neural
death is unknown, but genetic predisposition and environmental factors may cause the disease.
Sequence variations in N-acetyltransferase 2 (NAT2) gene leading to slow acetylation process have
been associated with PD, but results are contradictory.
Methods: We analyzed three NAT2  genetic variations, c.481C>T, c.590G>A (p.R197Q) and
c.857G>A (p.G286E), which are known to result in a slow acetylator phenotype. Using validated
PCR-RFLP assays, we genotyped 243 healthy unrelated Caucasian control subjects and 124 PD
patients for these genetic variations. Further, we have undertaken a systematic review of NAT2
studies on PD and we incorporated our results in a meta-analysis consisting of 10 studies, 1,206
PD patients and 1,619 control subjects.
Results: Overall, we did not find significant differences in polymorphic acetylation genotypes in PD
and control subjects. In the meta-analysis of slow acetylators from 10 studies and representing 604/
1206 PD vs. 732/1619 control subjects, a marginally significant odds ratio (OR) of 1.32 (95% CI
1.12–1.54, p < 0.05) was obtained. Re-analysis of the data to exclude the only two studies showing
positive association of slow acetylators to PD, resulted in a non-significant OR (1.07, 95% CI 0.9–
1.28). Furthermore, meta-analysis of studies for c.590G>A, where both allele and genotype
frequencies in PD vs. control subjects were analyzed, did not give significant summary odds ratios
as well.
Conclusion: We found little evidence for differences in polymorphic acetylation genotypes in PD
and control subjects. Results of the meta-analyses did not also provide conclusive evidence for an
overall association of NAT2 slow acetylator genotypes to PD.
Background
Parkinson's disease (PD, MIM #16860) is a progressive
neurodegenerative disorder characterized by resting
tremor, muscular rigidity, bradykinesia (slowness of
movement), postural instability, and pathologically, the
presence of Lewy bodies. This movement disorder is
caused by a deficiency of the neurotransmitter dopamine
in the striatum of the brain, as a result of degenerating
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nigrostriatal dopamine neurons. The molecular basis of
this neural death is unknown, but may be caused by
genetic predisposition and gene environmental interac-
tions, including exposure to pesticides, herbicides and
neurotoxins [1]. For instance, rare pathogenic mutations
and gene interactions in α-synuclein, parkin and ubiquitin
carboxy-terminal hydrolase LI (UCHL1) have been impli-
cated in PD [2]. A collaborative pooled analysis of 11 pub-
lished studies of the UCHL1  p.S18Y variant involving
1,970 PD cases and 2,224 unrelated controls, confirmed
an inverse association between this variant and PD partic-
ularly in younger subjects [3]. Furthermore, neurotoxins
such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and amine-related neurotoxins are proposed to
be among the environmental factors, killing selectively
dopaminergic neurons over a long period of time [4].
The N-acetyltransferases (NAT; E.C.2.3.1.5) are involved
in the metabolism of drugs and environmental toxins.
They catalyze the acetyltransfer from acetylcoenzyme A to
an aromatic amine, heterocyclic amine or hydrazine com-
pound. Sequence variations in the human NAT1 (MIM#
108345) and NAT2 (MIM # 243400) result in the produc-
tion of NAT proteins with variable enzyme activity or sta-
bility, leading to slow or rapid acetylation. Therefore,
genetic polymorphisms in NAT1  and NAT2  have been
associated with drug-induced toxicities and disease (see
reviews [5-7]).
Several association studies have been undertaken on
NAT2 sequence variations and Parkinson's disease, but
results are conflicting [8-20]. Some of these, report on
strong associations between slow acetylator genotypes of
NAT2 with PD in general or with early onset PD [8-13,18].
Slow acetylation may lead to insufficient detoxification of
neurotoxins inducing PD, but the mechanism remains
speculative. Recently, a study showed that intrastriatal 6-
hydroxydopamine (6-OHDA) treatment of NAT2 slow
acetylator rats led to decrease of striatal dopamine levels
as compared to identical treatment of NAT2 rapid acetyla-
tor [21]. Intrastriatal 6-OHDA treatment in rats results in
progressive dopaminergic nigral cell loss and constitutes
an animal model for PD. To help clarify further the role of
NAT2 acetylation genotypes in PD, we determined the
NAT2  genotypes in unrelated PD patients and control
healthy individuals of Caucasian origin focusing on three
sequence variations, namely c.481C>T, c.590G>A,
c.857G>A. We have also undertaken a systematic review
of NAT2 studies on PD and we incorporated our present
results in a meta-analysis consisting of 10 studies, 1,206
PD patients and 1,619 control subjects.
.
Methods
Informed consent blood samples were kindly provided by
Dr. C.A.D Smith of the Imperial Cancer Research Fund
Laboratory of the Ninewell's Hospital in Dundee, U.K. In
addition, JB has obtained approval to conduct genetic
studies involving human materials from the Medical
School of Hannover. All blood samples were obtained
from randomly selected, unrelated Caucasian individuals.
Using standard PCR-RFLP assay protocols, we employed
the restriction enzymes KpnI, TaqI and BamHI to distin-
guish  NAT2  variations c.481C>T (p.161L, dbSNP
rs1799929), c.590G>A (p.R197Q, dbSNP rs1799930)
and c.857G>A (p.G286E, dbSNP rs1799931), respec-
tively. On the basis of these NAT2 variations, we geno-
typed 243 healthy unrelated Caucasian control subjects
and 124 patients with Parkinson's disease (PD). The refer-
ence allele (NAT2*4) contains all three restriction sites,
thus the identification of homo- and heterozygous carriers
could easily be ascertained. In accordance with the human
NAT2  nomenclature http://louisville.edu/medschool/
pharmacology/NAT.html, allele NAT2*4 refers to NAT2
reference sequence (Genbank accession X14672). The
NAT2*4 allele acts dominantly to result in rapid acetyla-
tion, and the presence of c.481C>T, c.590G>A, c.857G>A
would lead to slow acetylation [22]. Therefore, for the
determination of acetylator status, we classified those pos-
sessing at least two mutant alleles as slow acetylators.
However, the acetylation status for the synonymous vari-
ation c.481C>T is not clear as this is also associated with
allele NAT2*12C which is actually a rapid allele [7].
Table 1: Comparison of NAT2 allele frequencies in controls and Parkinson's diseased patients
Allele Genetic variations Control group (n = 243) Parkinson's disease (n = 124)
c.481C>T c.590G>A c.857G>A
NAT2*4 C G G 22.3 % 28.9 %
C481T a T G G 48.9 % 47.3 %
G590A b C A G 27.0 % 21.5 %
G857A c CGA 1.7 % 2.3 %
a) C481T = NAT2*5A, *5B, *5F, *5G,*5H, *5I, *6E, *11A, *11B, *12C *14C
b) G590A = NAT2*5E, *5J, *6A, *6B, *6C, *6D, * 6E, *14 D
c) G857A = NAT2*7A, *7BBMC Medical Genetics 2006, 7:30 http://www.biomedcentral.com/1471-2350/7/30
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The confidence intervals for the percentages in our origi-
nal study were computed according to Pearson-Clopper,
whereas confidence intervals for the odds ratios were
computed assuming asymptotic log normality. Meta-anal-
ysis was performed using the package rmeta of the R-
Project [23]. The Mantel-Haenszel procedure meta.MH
was applied to analyze the odds ratios of the studies, the
Mantel-Haenszel summary, and Woolf's test for heteroge-
neity. The 95 % confidence intervals were also calculated
for the individual and the summary odds ratios.
Results
Own study
We genotyped three NAT2  sequence variations
(c.481C>T, c.590G>A and c.857G>A) in 243 healthy
unrelated Caucasian control subjects and 124 PD
patients. Although the difference in allele frequencies
between control and PD was not statistically significant,
we observed higher frequencies for NAT2*4  [c.481C +
c.590G + c.857G] and c.857G>A, and lesser frequencies
for c.481C>T and c.590G>A in PD (Table 1). Sequence
variations in PD and control did not deviate from a
Hardy-Weinberg equilibrium.
The genotype frequencies are shown in Table 2. Heterozy-
gotes for c.481C>T in control and PD did not vary much,
but there tend to be more heterozygous carriers for
c.590G>A in PD (Table 2). Moreover, while homozygotes
for c.481C>T did not differ in control and PD, homozy-
gotes for c.590G>A were more frequent in control. A
homozygote for c.857G>A was only detected in PD. Fur-
ther comparison of genotype frequencies indicated a two-
fold increase of [c.590GA + c.857GA] and approximately
one third reduction of [c.481CT + c.590GA] carriers in PD.
The [c.857GA] genotype was only found in control popu-
lation, but this represents only one of 243 individuals.
Interestingly, 10 of 243 control individuals carried the
two variations, [c.590AA + c.857GA], but the distribution
of this genotype did not differ between control and PD.
Overall, there was little evidence for statistically different
distributions of genotypes in PD and control.
Meta-analysis
We found 13 original published association studies deal-
ing with NAT2 gene polymorphisms in Parkinson's dis-
ease (see Background). Several studies were undertaken
on white Caucasians, but there were also studies on Nige-
rian Africans [16], Hongkong Chinese [12], and Indians
[13]. From these studies, a total of 1,961 cases and 2,433
control subjects have been analyzed for disease associa-
tion between PD and NAT2  genetic variations. If we
include our own study cohorts, the overall total would
add up to 2,085 PD cases and 2,676 control subjects.
We summarized published information concerning char-
acteristics of PD patients and control subjects (Table 3) as
well as genetic and disease association analyses (Table 4)
in 11 studies carried out from 1998–2005. Studies con-
sisted of one 100% familial, three familial/sporadic and
seven sporadic cases, and were either population or hos-
pital-based. Average % male in PD cases was 59% (34–
74%), while in control 53% (35–75%); average age at
onset (AAO) was 64 (32–77 yr). Three studies stratified
AAO into early onset (EOPD, <40 or <50 yr) and late
onset (LOPD, >40 or >50 yr). Average age of exam (AAE)
for PD cases was available for three studies (average 69 yr)
and for control in 10 studies (average 63 yr, range 34–74).
PD cases were diagnosed through manifestation of >2 car-
Table 2: NAT2 genotypes in controls and patients with Parkinson's disease
Genotypes Deduced 
phenotypes
Controls Parkinson's disease Odds ratios (95% 
confidence interval)
χ2
c.481 C>T c.590 G>A c.857 G>A n = 243 95% CI n = 124 95% CI
CC GG GG rapid 5.4 % (13) 2.9 – 9.0 9.7 % (12) 5.1 – 16.3 1.90 (0.85–4.25) NS
CT rapid 23.0 % (56) 17.9–28.9 25.0 % (31) 17.7 – 33.6 1.11 (0.67–1.84) NS
GA rapid 8.6 % (21) 5.4 – 12.9 15.3 % (19) 9.5 – 22.9 1.91 (0.99–3.68) p < 0.01
GA rapid 0.4 % (1) 0.01 – 2.3 ND 0.0 – 2.9 0.000* NS
TT slow1 22.2 % (54) 17.2 – 28.0 20.2 % (25) 13.5 – 28.3 0.88 (0.52–1.51) NS
AA slow 9.5 % (23) 6.1 – 13.9 5.7 % (7) 2.3 – 11.3 0.57 (0.24–1.36) NS
AA GA slow 4.1 % (10) 2.0 – 7.4 3.2 % (4) 0.9 – 8.1 0.78 (0.24–2.53) NS
CT GA slow 23.9 % (58) 18.7 – 29.7 17.0 % (21) 10.8 – 24.7 0.65 (0.37–1.13) NS
CT GA slow 2.5 % (6) 0.9 – 5.3 2.4 % (3) 0.5 – 6.9 0.98 (0.24–3.99) NS
GA GA slow 0.4 % (1) 0.01 – 2.3 0.8 % (1) 0.02 – 4.4 1.97 (0.13–30.24) NS
AA slow ND 0.0 – 1.5 0.8 % (1) 0.02 – 4.4 * NS
*The confidence intervals for the percentages were computed according to Pearson-Clopper, whereas confidence intervals for the odds ratios 
were computed assuming asymptotic log normality. To avoid undefined results, some estimates were not computed.    
1 c.481 C>T is a silent mutation associated also with NAT2*12C (c.481 C>T, c.803A>G) and which is a rapid allele (see Hein et al. [7] )   BMC Medical Genetics 2006, 7:30 http://www.biomedcentral.com/1471-2350/7/30
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dinal features of PD (e.g. resting tremor, bradykinesia,
postural disturbances, absence of and no apparent cause
of parkinsonism, and/ or positive response to levodopa
therapy). Control subjects were healthy family members,
or randomly recruited healthy individuals from the same
region, or in one case, pathologically normal brains from
a brain bank. In two studies, control subjects were age-
matched and in one study, 5–10 years older than the PD
cases.
Genomic DNA from blood samples was used in all studies
but one, and PCR-RFLP was mainly the method employed
for genotyping analysis. All studies basically analyzed the
NAT2 variants c.481C>T, 590G>A, 857G>A and in all, the
variant c.590G>A. Disease association was determined
generally by computing odds ratios, except for a family-
based study in which pedigree disequilibrium (PDT) or
likelihood ratio (Transmit) tests were used [20]. Either
there was overall association of slow acetylator genotypes
to PD [9,10,12], or there was no overall association
[8,14,15,18-20]. In addition, two earlier studies did not
also find association between slow acetylator genotypes
and PD [16,17]. Some studies, however, found positive
association of certain variants (e.g. c.857G>A, [18], in par-
ticular to early-onset PD [8,13].
Table 3: Characteristics of studies on NAT2 polymorphisms and Parkinson's disease: patients and control subjects
Authors, 
country
Ethnicity of 
participants
PD Control
Source Type of PD 
cases
N Male sex % Age at onset 
(yr)
Diagnostic 
criteria
Source N Age at exam 
(yr)
Male sex %
Van der Walt 
et al. 2003, 
USA
NG1 DCHG Morris 
Udall PD Cntr., 
DCHG/Glaxo-
Smith Kline PD 
Genetics 
Collaboration
familial 397 families 
607 affected 
indvls.
59 62 ± 13 
EOPD: ≤ 40 
LOPD:> 40 
AAE: 67 ± 12
levodopa 
therapy, 
absence of 
parkin 
mutations
healthy 
members of 
affected families
872 indvls. 67 ± 12 45
Bandmann et 
al. 1997, 
2000, UK
Caucasian UK PD Brain Bank, 
Inst. Psychiatry, 
London
familial, 
sporadic
100 familial 
100 sporadic
55 familial 65 
sporadic
68.4 ± 7.7 
(51–85) age at 
death 
(sporadic): 
76.7 ± 7.9 
(51–94)
criteria, 
Maraganore 
et al. 19912
UK PD Brain 
Bank, normal 
brains
100 77.1 ± 8.8 
(60–90)
65
Nicholl et al. 
1999, UK
Caucasian West Midlands 
Region, UK
familial, 
sporadic
30 familial 176 
sporadic
57 familial 60 
sporadic
63.9 familial 
64.5 sporadic
response to 
levodopa or 
dopamine 
agonists, = 2 
cardinal PD 
features
hospitals in two 
separate 
regions within 
the UK West 
Midlands
30 familial 
176 sporadic
63.9 familial 
63 sporadic
57 familial 60 
sporadic
Chaudhary et 
al. 2005, India
Indian two hospitals: New 
Delhi, Bangalore
sporadic 267 74 EOPD: 69 
LOPD: 79
31.8 ± 8.5 
EOPD : ≤ 40 
52.35 ± 9.0 
LOPD:> 40
criteria, UK 
PD Brain 
Bank
healthy spouses 
of PD subjects, 
outpatient dept 
participating 
hospitals
324 45.83 ± 2.88 
EOPD 
control 64.04 
± 8.13 LOPD 
control
75 EOPD 
control 74 
LOPD 
control
Chan et al. 
2003, China
Hongkong 
Chinese
two hospitals, 
Hongkong
sporadic 99 60 71.7 (46–93) 
4 patients ≤ 
45
criteria, 
Maraganore 
et al. 19912, 
levodopa 
therapy
same hospitals 
as PD cases
126 70.2 (39–96) 50
Bialecka et al. 
2002, Poland
Caucasian Pomeranian region sporadic 54 NG1 68 = 2 cardinal 
PD features
same region, 
randomly 
selected
85 73.4 ± 
5.8(65–87)
NG1
Maraganore 
et al. 2000, 
USA
Caucasian 
(almost)
Mayo Clinic 
referrals (from 
MN, WI, ND, SD) 
and PD study 
Olmsted County, 
MN
sporadic 139 65 62 (31–82) 
AAE: 69 (39–
91)
= 2 cardinal 
PD features, 
levodopa 
therapy
Olmsted 
County, MN, 
healthy spouses 
of PD subjects
113 72 (37–90) 35
Dupret et al. 
1999, France
Caucasian hospitals and clinics 
in Champagne-
Ardenne
sporadic 68 67 61 ± 9 (25–
88) AAE: 71 ± 
9
cardinal PD 
features
same region as 
PD cases
211 43.8 ± 6.1 50
Harhangi et 
al. 1999, 
Netherlands
Caucasian PD cases in 
Rotterdam
sporadic 80 34 77.3 ± 8.3 
(57–99)
= 2 cardinal 
PD features
same region as 
PD cases
161 78 ± 8.3 (57–
98)
39
Agundez et al. 
1998, Spain
Caucasian hospitals in Madrid 
and vicinity
sporadic 121 EOPD: 54 
LOPD: 52
41.3 ± 6.4 
(28–50) 
OEPD: 28–50 
67.3 ± 8.2 
(51–83) 
LOPD : >51
criteria, 
Hughes et al. 
19923
volunteers from 
the same region
121 34.2 ± 12.5 53
1NG  =not given   
 2 Maraganore DM, Harding AE, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord 1991; 6:205-211.    
3 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J 
Neurol Neurosurg Psychiatry 1992; 55:181-184.  BMC Medical Genetics 2006, 7:30 http://www.biomedcentral.com/1471-2350/7/30
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To obtain synthesis of data from multiple studies, we have
undertaken a meta-analysis of slow acetylators in PD vs.
control subjects in 10 studies including our own (Fig. 1A).
Only data on sporadic cases were included. The odds
ratios were significantly different between the studies (p =
2.89334e-07), and were consistent with respective
authors' conclusions. For the pooled analysis of 604/1206
PD vs. 732/1619 control subjects, we obtained a Mantel-
Haenszel OR of 1.32 (95% CI 1.12–1.54) which was sig-
nificantly greater than 1 (p < 0.05). Because the studies of
Bandmann et al. 2000 [10], and Chan et al. 2003 [12]
were the only ones showing positive association of slow
acetylators to PD, excluding these investigations resulted
in a non-significant OR (1.07, 95% CI 0.9–1.28) (Fig. 1B).
Our own study appeared to show an inverse association of
slow acetylators to PD (OR 0.60, 95% CI 0.39–0.93,
based on 62/124 PD vs.152/243 controls), but the ORs in
Fig. 1B did not differ significantly between each other.
Furthermore, our analysis of five studies for c.590G>A
comparing the allele frequency A in PD vs. control sub-
jects found that odds ratios were not significantly different
between the studies (p = 0.67) (Fig. 2). The summary OR=
0.94 (95% CI, 0.79–1.12) did not deviate significantly
from 1. Similarly, analysis of four studies for the genotype
c.590AA did not find significant differences between stud-
ies, and the summary OR = 1.06 (95% CI, 0.78–1.43) was
likewise not significant (Fig. 2).
Discussion
Overall, we demonstrate little evidence for differences in
polymorphic acetylation genotypes when a control and
Parkinson's diseased population is compared. This find-
ing may contrasts previous studies, but is similar to results
of other studies on Caucasians where no overall associa-
tion has been found (see Meta-analysis, Results). For
instance, one study found a strong association between
slow acetylator genotypes and familial PD (n = 100) in
European patients [10]. Another study found a statisti-
cally significant predominance of slow acetylators in spo-
radic PD (n = 54) in Polish population [11]. In unrelated
Hongkong Chinese with PD (n = 99), a strong association
between  NAT2  genotypes and PD was likewise found
[12]. Recently, in an Indian population, a significant asso-
ciation was found for c.590G>A and 857G>A in early-
onset, as well as c.282C>T in late-onset PD [13].
Nonetheless, there are also studies which do not show
association between NAT2  genotypes and PD. For
instance, no statistically significant differences were found
after comparison of NAT2 genotypes between sporadic
PD (n = 121) and control group [8]. They observed, how-
ever, that patients with early-onset PD (before 50 years, n
= 37), displayed a higher frequency of slow acetylator
types. Further, Dupret et al. [14] found similar distribu-
tion of slow acetylators in sporadic French PD (n = 68)
and control. Harhangi et al. [15] found likewise that over-
all frequencies were distributed similarly among PD (n =
Table 4: Characteristics of studies on NAT2 polymorphisms and Parkinson's disease: genetic and disease-association analyses
Authors, country Samples NAT2 variants Assay Statistical analysis Slow acetylator 
PD cases (%)
Slow acetylator 
controls (%)
Association Yes/
No
Van der Walt et al. 
2003, USA
blood 282, 341,481,590, 
857
oligo ligation assay pedigree disequilibrium 
test (PDT-sum), likelihood 
ratio test (Transmit), χ2-
test
NG1 NG1 No overall, but 
marginal c.282 in 
EOPD
Bandmann et al. 
2000, UK
blood, brain 
tissue
191, 
341,282,481,590, 
803, 857
allele-specific CR, 
PCR-RFLP
χ2-test, OR 95% CI, Yate's 
correction
familial: 69.0 
sporadic: 59.0
37.0 Yes
Bandmann et al. 
1997, UK
blood, brain 
tissue
481, 590, 857 PCR-RFLP χ2-test, OR 95% CI, Yate's 
correction
familial: 73 
sporadic: 60
39.0 Yes
Nicholl et al. 1999, 
UK
blood 481, 282, 590, 803, 
few cases: 191, 857
PCR-RFLP χ2-test, two-sample t- or 
Wilcoxon tests, OR 95% 
CI
familial: 53.3 
sporadic: 60.1
familial: 76.7 
sporadic: 55.4
No
Chaudhary et al. 
2005, India
blood 191, 282, 341,481, 
590, 803, 857
PCR-RFLP χ2-test, PHASE 2.0.2 for 
haplotypes, OR 95% CI
pooled: 19.2 
EOPD: 25.78 
LOPD: 12.29
pooled: 13.45 
EOPD control: 
13.01 LOPD 
control: 13.78
Yes, c.590 and 
c.857 in EOPD 
c.282 in LOPD
Chan et al. 2003, 
China
blood 481,590,857 PCR-RFLP logistic regression analysis, 
adjusted OR 95% CI
68.7 28.6 Yes
Bialecka et al. 
2002, Poland
blood 481,590,803,857 PCR-RFLP χ2-test, OR 95% CI, Yate's 
correction
64.8 46.9 Yes
Maraganore et al. 
2000, USA
blood 481,590, 857 PCR-RFLP logistic regression analysis, 
adjusted OR 95% CI, two-
sided p values
54.0 53.0 No overall, but 
c.857
Dupret et al. 1999, 
France
blood 191,341,590,857 allele-specific PCR, 
PCR-RFLP
NG1 51.5 59.8 No
Harhangi et al. 
1999, Netherlands
blood 481,590, 857 PCR-RFLP OR 95% CI, Fischer's 
exact test two tailed
54.0 53.0 No
Agundez et al. 
1998, Spain
blood 191, 282, 341, 590, 
803, 857
PCR-RFLP χ2-test, OR 95% CI, 
Fischer's exact test
EOPD: 78.4 
LOPD: 54.8
55.4 No overall, but yes 
OEPD
NG1=not givenBMC Medical Genetics 2006, 7:30 http://www.biomedcentral.com/1471-2350/7/30
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132) patients and control. Of considerable importance is
the finding of a recent family-based study which analyzed
397 families (n  = 1580 individuals, 607 affected) and
found no overall association between any NAT2 genetic
variations (single or combined) and familial or early-
onset PD [20].
Our meta-analysis of 10 studies of slow acetylators repre-
senting data from 1,206 PD patients and 1,619 control
subjects gave an OR value of 1.32 (95% CI 1.12–1.54)
which was marginally significant (p < 0.05). This result is
similar to an earlier meta-analysis where a total of 792 PD
patients and 912 control subjects from seven studies pub-
lished between 1989–1999 were investigated. Specifically,
Meta-analysis of association studies on NAT2 slow acetylators and sporadic Parkinson's disease Figure 1
Meta-analysis of association studies on NAT2 slow acetylators and sporadic Parkinson's disease. The confidence 
interval for each study is given by a horizontal line, and the point estimate is given by a square whose height is inversely propor-
tional to the standard error of the estimate. The summary odds ratio is drawn as a diamond with horizontal limits at the confi-
dence limits and width inversely proportional to its standard error. (A): Meta-analysis on 10 studies. Test for heterogeneity χ2 
(df 9) = 47.71 (p-value 0). The odds ratios are significantly different between the studies. The summary odds ratio (Mantel-
Haenszel OR= 1.32, 95% CI, 1.12–1.54) is significantly greater than 1 (p < 0.05). (B) Meta-analysis on 8 studies, excluding stud-
ies of Bandmann et al. 2000 and Chan et al. 2003. The odds ratios are not significantly different between studies. Test for het-
erogeneity χ2 (df 7) = 14.28 (p = 0.0464). The summary odds ratio (OR= 1.07, 95% CI, 0.9–1.28) is not significant.BMC Medical Genetics 2006, 7:30 http://www.biomedcentral.com/1471-2350/7/30
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the frequency of slow to rapid acetylator genotypes for the
composite seven studies showed a significant association
of patients with PD to control subjects (OR = 1.33; 95%
CI, 1.08 to 1.62) [23]. However, our meta-analysis on
eight studies, omitting the studies of Bandmann et al.
2000 [10] and Chan et al. 2003 [12], resulted in an OR of
1.07, 95% CI 0.9–1.28, which was not significant. This
result shows that these two studies were solely responsible
for the marginal positive association obtained in the
meta-analysis of 10 studies. Indeed, the inclusion of Chan
et al. 2000 [12] in a meta-analysis of nine studies would
still give an OR of 1.25, 95% CI, 1.06–1.47, and p <0.05.
Although our study appeared to show an inverse associa-
tion of slow acetylators to PD (OR 0.60, 95% CI 0.39–
0.93), this OR did not differ significantly from other stud-
ies (see Fig. 1B).
Meta-analysis of NAT2 c.590G>A in PD and control subjects Figure 2
Meta-analysis of NAT2 c.590G>A in PD and control subjects. The confidence interval for each study is given by a hori-
zontal line, and the point estimate is given by a square whose height is inversely proportional to the standard error of the esti-
mate. The summary odds ratio is drawn as a diamond with horizontal limits at the confidence limits and width inversely 
proportional to its standard error. Allele frequency: Test for heterogeneity χ2 (df 4) = 2.36 (p-value 0.67). The odds ratios are 
not significantly different between the studies (p = 0.67). The summary odds ratio (Mantel-Haenszel OR= 0.94, 95% CI, 0.79–
1.12) is not significantly greater than 1 (p > 0.05). Genotype frequency: Test for heterogeneity χ2 (df 3) = 9.58 (p-value 0.0225). 
The odds ratios are not significantly different between the studies (p = 0.0225). The summary odds ratio (Mantel-Haenszel 
OR= 0.94, 95% CI, 0.78–1.43) not significantly different from 1.BMC Medical Genetics 2006, 7:30 http://www.biomedcentral.com/1471-2350/7/30
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Furthermore, our analysis of five studies for c.590G>A
comparing the allele frequency A in 473 PD vs. 620 con-
trol subjects found that the summary OR 0.94 (95% CI,
0.79–1.12) did not deviate significantly from 1. Similarly,
the odds ratios in four studies for the genotype c.590AA
was not different from each other and the obtained OR
value (OR = 1.06, 95% CI 0.78–1.43) was not signifi-
cantly different from 1. Therefore, there appears to be no
overall association of slow acetylator genotypes to PD.
Our systematic review and meta-analysis of NAT2 studies
on PD could serve as an initial assessment or synthesis of
studies towards understanding of the specific role of
NAT2 acetylation variants in PD. As reflected in the sum-
mary of NAT2 studies and PD (see Tables 3 and 4), there
is lack of uniformity in study design as well as in the
genetic analysis and interpretation of results. Such diffi-
culties and confusions regarding NAT2 studies and PD
have been outlined earlier [24]. For instance, in some
studies there was no report on genotype frequencies or
studies have different focal emphasis, i.e. familial or spo-
radic PD. To determine specifically the role of NAT2
acetylation variants in PD, perhaps a collaborative effort is
needed with uniform study design involving different eth-
nic groups as has been demonstrated in the meta-analysis
of UCHL1 studies in PD [3].
Conclusion
Overall, our study did not find significant differences in
polymorphic acetylation genotypes in PD and control
subjects. The meta-analysis on 10 studies showed a mar-
ginal positive association of slow acetylators to PD, but
this result was driven by two studies, the exclusion of
which in the re-analysis provided a non-significant esti-
mate. Apparently, there appears to be no overall associa-
tion of NAT2  slow acetylator genotypes to Parkinson's
disease.
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